Why it Matters

A package of ten public health bills (covering everything from ALS research to school-based health clinics to tick-borne disease) landed before the House Energy and Commerce Subcommittee on Health, as the April 15 hearing titled "Healthier America: Legislative Proposals to Improve Public Health" convened. The stakes were concrete: several of these programs face expiring authorizations, and without congressional action, funding pipelines for community health centers, stem cell therapies, and ALS treatment access could go dark.

The hearing arrived as Congress is simultaneously navigating the broader budget reconciliation process, making the question of which public health programs survive more consequential than a typical legislative hearing preview would suggest.

The Bills on the Table

The hearing memorandum lists ten pieces of legislation under consideration:

The breadth of the package reflects a deliberate strategy by subcommittee Chair Buddy Carter (R-GA) and Vice Chair Diana Harshbarger (R-TN) to advance largely bipartisan, reauthorization-heavy legislation that can move without becoming entangled in more divisive health care fights. Ranking Member Diana DeGette (D-CO) has signaled her own commitment to the panel's health agenda, writing on World Health Day that she will "always fight for quality, affordable health care for all Americans" in her role on the committee.

The Lobbying Backdrop

Lobbying disclosure filings from the past year show sustained pressure from health advocacy organizations across nearly every topic on the agenda.

On community health centers, the National Association of Community Health Centers spent $90,000 per quarter in 2025 lobbying on "funding for community health centers; healthcare workforce development issues and funding." Advocates for Community Health filed separately on Medicaid and the Community Health Center Fund. La Familia Central Valley specifically flagged "potential actions to freeze community health functions" as a lobbying concern, a reference to broader funding uncertainty under the current administration.

On stem cell research, the Cord Blood Association filed quarterly reports throughout 2025 on "legislative and federal agency activities related to the Stem Cell Act," spending $20,000–$30,000 per quarter. The International Society for Stem Cell Research weighed in on FY26 appropriations and related research policy.

ALS advocates have been among the most active. I AM ALS lobbied specifically on "ACT for ALS and ARPA-H" funding within the FY26 Labor-HHS appropriations process. ALS United Inc. filed a fourth quarter 2025 disclosure on "support for ALS research and treatment."

On tick-borne illness, the Center for Lyme Action filed a third quarter 2025 report specifically naming the Kay Hagan Tick Act and related bills as lobbying targets.

Physical activity and chronic disease prevention drew attention from YMCA of the USA, which spent $110,000 per quarter on "chronic disease prevention, injury prevention, physical activity promotion and other efforts to promote social determinants of health," and from the American College of Sports Medicine, which filed on physical activity policy in third quarter 2025.

What Members Have Been Saying

In the weeks leading up to the Healthier America hearing, committee members have been vocal on the underlying issues.

Rep. Robin Kelly (D-IL), a committee member, posted in late March about bipartisan legislation she described as helping "bring healthy, affordable foods back into our communities," directly aligned with the nutrition education bill. She also raised kidney disease awareness, noting that 37 million Americans are living with the condition and 90 percent don't know it.

Rep. Troy Carter Sr. (D-LA), another committee member, introduced the Mental Health Workforce Act in March, and separately called hypertension "the silent killer" that "disproportionately impacts Black Americans."

Rep. Mariannette Miller-Meeks (R-IA) marked World Parkinson's Disease Day on April 11, calling for advances in research and care, which is consistent with the committee's broader focus on neurological disease legislation, including the Alzheimer's provider training bill sponsored by fellow committee member Rep. Troy Balderson (R-OH).

The Witnesses

Six witnesses were scheduled to testify at the committee hearing April 2026, including Jamie Ulmer, President and CEO of Healthcare Network; Rachel F. Brem; Holly Ahern; Amy L. Ronneberg; Brian Wallach and Sandra Abrevaya, appearing jointly; and René Quashie. The witness list spans community health, oncology, infectious disease, and patient advocacy.

Access the Legis1 platform for comprehensive political news, data, and insights.